LEISHMANIASIS AND LEPROSY...NEGLECTED TROPICAL DISEASES (NTDs)

> DR SHAWANA SHARIF ASSISTANT PROFESSOR DERMATOLOGY DEPARTMENT BENAZIR BHUTTO HOSPITAL

## LEARNING OUTCOMES

- At the end of lecture, student should be able to
  - Know the organism and vector of cutaneous leishmaniasis
  - Differentiate between old and new world cutaneous leishmanisis
  - Identify different clinical forms of cutaneous leishmaniasis
  - Investigate and treat a case of clinical leishmaniasis

## LEARNING OUTCOMES

- Identify organisms of leprosy
- Differentiate between different types of leprosy
- Identify lesions of different types of leprosy
- Investigate appropriately a case of leprosy
- Treat a case of leprosy

## **LEISHMANIASIS**

- It is a disease affecting reticuloendothelial cells of the skin caused by protozoan Leishmania.
- There is an interplay of leishmania protozoa between
  - Host (Humans)
  - Vector (Sand fly)
  - Reservoir of infection



## CUTANEOUS LEISHMANIASIS NEW WORLD VERSUS OLD WORLD



## **LEISHMANIA PARASITES**

#### OLD WORLD

- L. major
- L. tropica
- L. aethiopica
- L. donovani
  - L.d. donovani L.d. infantum L.d. chagasi

**NEW WORLD** L. mexicana L.m. mexicana L.m. amazonensis L.m. venezuelensis • L. brasiliensis L.b. brasiliensis L.b. guyanensis L.b. panamensis

EACH SPECIES OF LEISHMANIA FAVORS ONE OR MORE ANIMAL RESORVIOR EXCEPT L. DONOVANI AND POSSIBLY L. TROPICA

## CUTANEOUS LEISHMANIASIS-VECTOR SAND FLY

- INFECTION IS TRANSMITTED BY THE BITE OF FEMALE SANDFLY, USUALLY AT NIGHT.
- DUSK AND DAWN ARE THE MOST SUSEPTIBLE TIMES
- WEAK FLIERS.
  - HOPPING TYPE OF FLIGHT.
  - DO NOT DISPERSE MORE THAN 10-20 METERS.
- REQUIRE MENT FOR BREEDING
  - HUMIDITY
  - MODERATE TEMPERATURE



## I-Cutaneous Leishmaniasis "Oriental Sore"(O.W.C.L)

#### 1- Single Dry Non-Exudative Lesion

#### Caused by L. tropica URBAN type

- 1- Present in towns & cities (common in Saudi Arabia).
- 2- Long incubation Period (months to years).
- 3- Lesions develop in exposed parts such as (face -limbs)
- 4- Lesions are slowly progressive.
- 5- Ulcer heals "self-limiting infection" \_\_\_\_\_ scar tissue form
- 6- C.M.I. curtails the infection leading to resistance to reinfection

Appear as follows: single-small-Dry-painless nodule-nonexudative-delayed ulceration-small scar- non pruritic- uncommon 2ry bacterial infection.

#### 2- Multiple Wet Exudative Lesion

Caused by L. major RURAL type

- 1- Found in villages at edge of deserts(common in KSA).
- 2- Relatively short incubation period (2-6 weeks).
- 3- Lesions are more severe than L.tropica big Ulcers
- 4- Lesions are rapidly progressive.

5- Dense nodules \_\_\_\_\_ ulcerate & Coalesce \_\_\_\_\_ big ulcers

Appear as follows: Multiple-Big-Wet-painless nodule-Exudativ 2ry bacterial delay healing –Big disfiguring scar- pruritic.





## CUTANEOUS LEISHMANIASIS OLD WORLD URBAN 'DRY' LEISHMANIASIS





#### CUTANEOUS LEISHMANIASIS OLD WORLD

#### **RURAL 'WET' LEISHMANIASIS**

NODULE PLAQUE CRUSTING ULCERATION

2-3 months

## CUTANEOUS LEISHMANIASIS OLD WORLD RURAL 'WET' LEISHMANIASIS





CUTANEOUS LEISHMANIASIS OLD WORLD RURAL 'WET' LEISHMANIASIS

## NEW WORLD CUTANEOUS LEISHMANIASIS MUCO – CUTANEOUS LEISHMANIASIS L. brasiliensis





INITIAL LESION HEALS

AFTER 2-5 YEARS

BLOOD BORNE METESTASIS

MUCOSAL LESION

CAUSES SEVERE
DESTRUCTION

#### CUTANEOUS LEISHMANIASIS PARASITOLOGICAL CONFIRMATION (AMASTIGOTES) SKIN SMEARS









#### CUTANEOUS LEISHMANIASIS PARASITOLOGICAL CONFIRMATION (AMASTIGOTES) SKIN SMEARS



MATERIAL IS SMEARED ONTO SLIDE AND GIEMSA STAINED



### CUTANEOUS LEISHMANIASIS TREATMENT SINGLE SMALL LESION



*◇SURGICAL REMOVAL ◇CURRETAGE* 





#### CUTANEOUS LEISHMANIASIS TREATMENT SINGLE LARGE LESION



 INTRALESIONAL INJECTIONS
 PENTAVALENT ANTIMONIALS
 PENTOSTAM – 1–2 ml

- PENTOSTAM 1–2 ml THRICE WEEKLY
- a GLUCANTIME 1–2 ml THRICE WEEKLY

 TOPICAL APPLICATION
 PAROMOMYCIN OINTMENT

## CUTANEOUS LEISHMANIASIS TREATMENT MULTIPLE LESIONS AND LYMPHATIC SPREAD





#### PENTAVALENT ANTIMONIALS



# Leptosy

(Hansen's disease)

## M leprae

 Obligate Intracellular Acid-fas Gram-positive Bacillus
 multiplies very slowly
 Slow growing (12 days doubling time).
 Grows at 30–33° C(Prefers the cooler parts of the body

## Affinity for

- Macrophages
   Solution
- Schwann cells



## Principal means of transmission

## **Aerosol spread**

(from infected nasal secretions to exposed nasal and oral mucosa)

Not a highly infectious disease



Host's immune system
<u>A strong cell-mediated immunity</u>

- <u>Tuberculoid forms</u>
- few lesions
- well-defined nerves involved
- lower bacterial loads

## **Relatively absent cell-mediated immunity**

- Lepromatous leprosy
- widespread lesions
- extensive skin and nerve involvement
- high bacterial loads.

## SPECTRUM OF LEPROSY



## **Tuberculoid leprosy**

#### • Lesion

- **Single or 2 or 3 (up to 10)**
- Erythematous /Hypopigmented
- Dry surface, hairless
- Raised well defined edge
- tendency of central flattening
- Sensation
  - absent

## • Nerve

- Feeding nerve to the patch or solitary peripheral nerve may be thickened
- **AFB:** negative
- Lepromin: +++



## **BB** Leprosy

#### • Lesion

- Several number
- bilateral but asymmetrical distribution
- Less well defined
- Variable size, sloping outer edge
- Slightly shiny
- central punched out area
- Sensory loss:
  - slightly diminished
- Nerve
  - Asymmetrical many nerve thickening
- **AFB: moderate 2+to3+**
- Lepromin: negative





## **BL Leprosy**

#### • Lesion

- More numerous
- bilateral, but asymmetrical
- more shiny,
- less defined lesions
- + diffuse infiltration certain areas
- Sensory loss:
  - slight sensory loss over them
- Nerve
  - Wide spread nerve damage, asymmetrical
- **AFB**: many (4+)
- Lepromin: negative



Lepromatous leprosy (infiltrative, papular, plaques type, & nodular stages)

## Initial fine infiltration

 Diffuse redness of the face, ear lobes, extensor aspects of extremities, lower part of the back may be the initial presentation

## Course infiltration

 leads to papules, plaques and nodules development due to marked aggregation of the infiltrate



- leonine facies
  - lines of the forehead become deeper as the skin thickens
- madarosis
  - eyebrows and eyelashes become thinned or lost (madarosis)
- ear lobes thickened
- nose becomes misshapen
  - may collapse due to septal perforation and loss of anterior nasal spine
- voice becomes hoarse

Lepromatous leprosy

- Ioss of eyebrows
- nodules
   corresponding to
   cooler locations of
   the face.
  - eyebrows
  - cheek
  - nose
  - ears,





 The longest peripheral sensory nerve fibers are first effected

cause numbress and anaesthesia



## NERVE INVOLVEMENT

Posterior tibial nerve is the most frequently affected nerve, followed by
Inar, median, lateral popliteal and facial

Complete claw hand Ulnar & median involvement

## Cardinal signs of

The three Cardinal Signs of Leprosy

- 1. Hypo-pigmented or reddish skin lesion(s) with definite sensory deficit
- 2. A thickened or enlarged peripheral nerve with loss of sensation and/or weakness of the muscles supplied by that nerve.
- 3. The presence of Acid-fast bacilli in slit skin smears or histopathology

Presence of any one out of three cardinal signs is essential to diagnose leprosy.



## SKIN OR NERVE BIOPSY

• In cases where the diagnosis may be uncertain.

 They should also be taken from areas of skin with the suspected most active disease, e.g. from the margin of a skin lesion.



## Main principles of treatment

*1 Stop the infection with chemotherapy.* **2** Treat reactions and reduce the risk of nerve damage. **3** Educate the patient to cope with existing nerve damage **4** Treat the complications of nerve damage. **5** Rehabilitate the patient socially and psychologically.

## LEPROSY TREATMENT MULTI-DRUG TREATMENT(MTD)

#### PAUCIBACILLARY LEPROSY (DURATION 6 MONTHS)

- Rifampicin 600 mg/month (supervised)
- Dapsone 100mg/month (supervised)
- Dapsone 100mg/daily (unsupervised)
- FOLLOWUP 2 YEARS

#### MULTIBACILLARY LEPROSY (DURATION 12 MONTHS)

- Rifampicin 600 mg/month (supervised)
- Clofazamine 300mg/month (supervised)
- Dapsone 100mg/daily (unsupervised)
- Clofazamine 50mg/day (unsupervised)
- FOLLOWUP 5 YEARS